查爾斯河實驗室 CRL 深 滬
等待開盤 08-21 09:30:00 美东时间
291.45
+1.450
+0.50%
華盛通- 最 高299.32
- 今 開285.72
- 成交量 105.94万股
- 最 低 281.73
- 昨 收 290.00
- 總市值 139.13亿
- 52周最高 299.32
- 市盈率 靜 --
- 換手率 2.22%
- 52周最低 144.26
- 委 比 76.99%
- 總股本 4773.89万
- 歷史最高 460.21
- 量 比 1.22
- 振 幅 6.07%
- 歷史最低 25.52
- 每 手 1
- 風險率 30.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32 billion. Buying $100 In CRL: If an investor had bought $100 of CRL stock 15 years a...
08-15 06:15
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
JP Morgan Upgrades Charles River to Overweight, Raises Price Target to $310
JP Morgan analyst Casey Woodring upgrades Charles River (NYSE:CRL) from Neutral to Overweight and raises the price target from $180 to $310.
08-06 18:44
Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High
Charles River Laboratories International Inc. (NYSE:CRL) stock traded higher Wednesday after the contract research organization raised its full-year 2026 financial guidance following second-quarter results that exceeded Wall Street expectations. The company increased its fiscal 2026 adjusted earning...
08-06 02:03
查尔斯河实验室高管在电话会议上表示，第三季度调整后每股收益预期为2.90至3.00美元。
查尔斯河实验室高管在电话会议上表示，第三季度调整后每股收益预期为2.90至3.00美元。
08-05 21:34
财报速睇 | 查尔斯河实验室2026财年Q2营收10.04亿美元，同比下降2.7%；归母净利润亏损0.01亿美元，由盈转亏
华盛资讯8月5日讯，查尔斯河实验室公布2026财年Q2业绩，公司Q2营收10.04亿美元，同比下降2.7%，归母净利润亏损0.01亿美元，由盈转亏。
08-05 21:31
查尔斯河实验室高管称，继续预计北美研究模型业务量将下降，学术和政府客户的支出因美国国立卫生研究院预算持平及拨款审批流程放缓而受限。
查尔斯河实验室高管称，继续预计北美研究模型业务量将下降，学术和政府客户的支出因美国国立卫生研究院预算持平及拨款审批流程放缓而受限。
08-05 21:19
财报速睇 | 查尔斯河实验室 2026财年Q2营收10.04亿美元，同比下降2.7%；归母净利润亏损0.01亿美元，由盈转亏
华盛资讯8月5日讯，查尔斯河实验室公布2026财年Q2业绩，公司Q2营收10.04亿美元，同比下降2.7%，归母净利润亏损0.01亿美元，由盈转亏。
08-05 19:35
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Sherwin-Williams Co (NYSE:SHW) rose sharply after the company reported better-than-expected second-quarter financial results and raised its FY26 guidance. Sherwin-Williams reported quarterly earnings of ...
07-28 22:05
